{"id":"ruxolitinib","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Subjects with any TEAE","drugRate":"27%","severity":"common"},{"effect":"Nasopharyngitis","drugRate":"13%","severity":"common"},{"effect":"Bronchitis","drugRate":"4%","severity":"mild"},{"effect":"Ear infection","drugRate":"4%","severity":"mild"},{"effect":"Eosinophil count increased","drugRate":"4%","severity":"mild"},{"effect":"Urticaria","drugRate":"4%","severity":"mild"},{"effect":"Diarrhea","drugRate":"1%","severity":"mild"},{"effect":"Folliculitis","drugRate":"3%","severity":"mild"},{"effect":"Tonsillitis","drugRate":"1%","severity":"mild"},{"effect":"Rhinorrhea","drugRate":"<1%","severity":"mild"},{"effect":"Neutropenia","drugRate":"reported","severity":"unknown"},{"effect":"Allergic conjunctivitis","drugRate":"reported","severity":"unknown"},{"effect":"Pyrexia","drugRate":"reported","severity":"unknown"},{"effect":"Seasonal allergy","drugRate":"reported","severity":"unknown"},{"effect":"Herpes zoster","drugRate":"reported","severity":"unknown"},{"effect":"Otitis externa","drugRate":"reported","severity":"unknown"},{"effect":"Staphylococcal infection","drugRate":"reported","severity":"unknown"},{"effect":"Acneiform dermatitis","drugRate":"reported","severity":"unknown"}],"contraindications":["Breastfeeding (mother)","Pregnancy, function"]},"trials":[],"_chembl":{"chemblId":"CHEMBL1287854","moleculeType":"Small molecule","molecularWeight":"306.37"},"aliases":[],"patents":[{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Jun 12, 2028","territory":"US","drugProduct":false,"patentNumber":"8822481","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Jun 12, 2028","territory":"US","drugProduct":false,"patentNumber":"8829013","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Jun 12, 2028","territory":"US","drugProduct":false,"patentNumber":"10016429","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Dec 12, 2026","territory":"US","drugProduct":false,"patentNumber":"9079912","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Dec 24, 2027","territory":"US","drugProduct":true,"patentNumber":"7598257","drugSubstance":true},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Dec 12, 2026","territory":"US","drugProduct":false,"patentNumber":"9814722","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Jun 12, 2028","territory":"US","drugProduct":true,"patentNumber":"8722693","drugSubstance":true},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Dec 24, 2027","territory":"US","drugProduct":true,"patentNumber":"8415362","drugSubstance":true},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Jun 24, 2028","territory":"US","drugProduct":false,"patentNumber":"7598257*PED","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Jun 24, 2028","territory":"US","drugProduct":false,"patentNumber":"8415362*PED","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Dec 12, 2028","territory":"US","drugProduct":false,"patentNumber":"8722693*PED","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Dec 12, 2028","territory":"US","drugProduct":false,"patentNumber":"8822481*PED","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Dec 12, 2028","territory":"US","drugProduct":false,"patentNumber":"8829013*PED","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Jun 12, 2027","territory":"US","drugProduct":false,"patentNumber":"9079912*PED","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Jun 12, 2027","territory":"US","drugProduct":false,"patentNumber":"9814722*PED","drugSubstance":false},{"applNo":"N202192","source":"FDA Orange Book","status":"Active","expires":"Dec 12, 2028","territory":"US","drugProduct":false,"patentNumber":"10016429*PED","drugSubstance":false}],"pricing":[],"_fixedAt":"2026-03-30T15:39:41.495153","allNames":"incb018424, jakafi, jakavi","offLabel":[],"timeline":[],"_dailymed":{"setId":"24da5509-6631-4795-9d42-273faecd08e7","title":"OPZELURA (RUXOLITINIB) CREAM [INCYTE CORPORATION]"},"ecosystem":[],"mechanism":{"target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T00:38:04.570Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"revenueYear":2024,"annualRevenue":2600,"revenueSource":"Verified: Incyte 10-K","revenueCurrency":"USD","revenueConfidence":"verified","revenueExtractedAt":"2026-04-01T11:47:44.709120","revenueExtractedBy":"revenue-sec"},"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Acute graft-versus-host disease","diseaseId":"acute-graft-versus-host-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic graft-versus-host disease","diseaseId":"chronic-graft-versus-host-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Myelofibrosis","diseaseId":"myelofibrosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Myeloproliferative disorder","diseaseId":"myeloproliferative-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Polycythemia vera","diseaseId":"polycythemia-vera","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Splenomegaly","diseaseId":"splenomegaly","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vitiligo","diseaseId":"vitiligo","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","patents(16)","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07498205","phase":"PHASE4","title":"Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-08-08","conditions":"Myelofibrosis, Myelofibrosis (MF)","enrollment":268},{"nctId":"NCT03286530","phase":"PHASE2","title":"Ruxolitinib + Allogeneic Stem Cell Transplantation in AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-11-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation","enrollment":64},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT05936359","phase":"PHASE1","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-09-25","conditions":"Myeloproliferative Neoplasms","enrollment":225},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT03874052","phase":"PHASE1","title":"Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Jennifer Saultz","startDate":"2019-08-16","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia","enrollment":51},{"nctId":"NCT06936566","phase":"PHASE2","title":"MAGIC Ruxolitinib for aGVHD","status":"RECRUITING","sponsor":"John Levine","startDate":"2025-05-14","conditions":"Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects","enrollment":98},{"nctId":"NCT04472598","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-29","conditions":"Myelofibrosis (MF)","enrollment":252},{"nctId":"NCT06388564","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-10-11","conditions":"Chronic Graft-versus-host-disease","enrollment":120},{"nctId":"NCT07049575","phase":"PHASE1","title":"Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-11-03","conditions":"Hidradenitis Suppurativa","enrollment":24},{"nctId":"NCT05750823","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2023-04-11","conditions":"Nonsegmental Vitiligo With Genital Involvement","enrollment":49},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06034002","phase":"PHASE1","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-12-04","conditions":"Myeloproliferative Neoplasms","enrollment":230},{"nctId":"NCT06150157","phase":"PHASE1","title":"A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-12-20","conditions":"Neoplasms","enrollment":220},{"nctId":"NCT02386800","phase":"PHASE4","title":"CINC424A2X01B Rollover Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2015-03-05","conditions":"Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease","enrollment":279},{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":"Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT00044304","phase":"PHASE2","title":"Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-09-26","conditions":"Eosinophilic Myeloid Neoplasm, Hypereosinophilic Syndrome","enrollment":70},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT06958211","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-12","conditions":"Hidradenitis Suppurativa","enrollment":550},{"nctId":"NCT06959225","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-23","conditions":"Hidradenitis Suppurativa","enrollment":550},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT05622318","phase":"PHASE2","title":"De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-08-29","conditions":"Graft-versus-host Disease","enrollment":56},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT07464951","phase":"PHASE1","title":"CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2026-04-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT03681561","phase":"PHASE1, PHASE2","title":"Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Veronika Bachanova","startDate":"2018-09-13","conditions":"Hodgkin Lymphoma","enrollment":54},{"nctId":"NCT04176198","phase":"PHASE1, PHASE2","title":"A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis","status":"RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2019-12-16","conditions":"Myelofibrosis","enrollment":240},{"nctId":"NCT04384692","phase":"PHASE2","title":"Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-18","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":53},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT03069326","phase":"PHASE2","title":"A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-27","conditions":"Myelofibrosis","enrollment":30},{"nctId":"NCT07317700","phase":"PHASE3","title":"A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2026-02-13","conditions":"MF","enrollment":105},{"nctId":"NCT07085039","phase":"PHASE2","title":"Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-12-18","conditions":"Castleman's Disease (CD), Idiopathic Multicentric Castleman&#39;s Disease","enrollment":14},{"nctId":"NCT05998408","phase":"PHASE1, PHASE2","title":"JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2024-02-20","conditions":"Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS","enrollment":145},{"nctId":"NCT06327100","phase":"PHASE1, PHASE2","title":"Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-01","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis","enrollment":33},{"nctId":"NCT06660355","phase":"PHASE2","title":"Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-12-23","conditions":"Chronic Graft-versus-host Disease (cGVHD)","enrollment":120},{"nctId":"NCT02974647","phase":"PHASE2","title":"Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-11","conditions":"Lymphoma","enrollment":83},{"nctId":"NCT04279847","phase":"PHASE1","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-02-23","conditions":"Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome","enrollment":140},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":399},{"nctId":"NCT06695507","phase":"PHASE1","title":"Upfront Ruxolitinib for Chronic Graft-vs-host Disease","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2025-02-19","conditions":"Chronic Graft Versus Host Disease","enrollment":1},{"nctId":"NCT04061421","phase":"PHASE1, PHASE2","title":"Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)","status":"RECRUITING","sponsor":"Michael Savona","startDate":"2021-11-24","conditions":"MDS/MPN","enrollment":94},{"nctId":"NCT07424222","phase":"PHASE1","title":"Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05-01","conditions":"Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)","enrollment":16},{"nctId":"NCT07025538","phase":"PHASE1","title":"Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2026-03-09","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":42},{"nctId":"NCT04908735","phase":"PHASE2","title":"Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-11-12","conditions":"Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO)","enrollment":7},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT03514069","phase":"PHASE1","title":"Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2018-06-05","conditions":"Glioma, Glioblastoma","enrollment":60},{"nctId":"NCT07359859","phase":"PHASE2","title":"A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-01-20","conditions":"Hematologic Malignancies","enrollment":40},{"nctId":"NCT05980806","phase":"PHASE2","title":"A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2024-04-22","conditions":"Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia","enrollment":58},{"nctId":"NCT03954236","phase":"PHASE2","title":"Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-05-14","conditions":"Non-sclerotic Cutaneous Chronic Graft-versus-host Disease","enrollment":24},{"nctId":"NCT05592015","phase":"PHASE2","title":"Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Jonathan Brammer","startDate":"2023-05-03","conditions":"T-Cell Large Granular Lymphocyte Leukemia","enrollment":30},{"nctId":"NCT05037760","phase":"PHASE2","title":"A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis","status":"RECRUITING","sponsor":"Takeda","startDate":"2021-12-16","conditions":"Myelofibrosis","enrollment":135},{"nctId":"NCT03120624","phase":"PHASE1","title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-09-15","conditions":"Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma","enrollment":34},{"nctId":"NCT02876302","phase":"PHASE2","title":"Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-01-24","conditions":"Inflammatory Breast Cancer (IBC)","enrollment":23},{"nctId":"NCT05998395","phase":"PHASE1, PHASE2","title":"JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2023-09-28","conditions":"Kohlmeier Degos Disease With Neurologic Involvement, Kohlmeier-Degos Disease","enrollment":1},{"nctId":"NCT07340138","phase":"PHASE1","title":"Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","enrollment":6},{"nctId":"NCT07357727","phase":"PHASE3","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-15","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)","enrollment":460},{"nctId":"NCT06551584","phase":"PHASE1","title":"Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-12-01","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":24},{"nctId":"NCT03610971","phase":"PHASE2","title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-19","conditions":"Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase","enrollment":24},{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT04217356","phase":"","title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-05","conditions":"Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer","enrollment":90},{"nctId":"NCT07368673","phase":"PHASE4","title":"Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Dow University of Health Sciences","startDate":"2025-04-06","conditions":"Vitiligo","enrollment":120},{"nctId":"NCT07366801","phase":"PHASE2, PHASE3","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-09-03","conditions":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk","enrollment":64},{"nctId":"NCT03722407","phase":"PHASE2","title":"Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-08-28","conditions":"Chronic Myelomonocytic Leukemia, Leukemia","enrollment":29},{"nctId":"NCT06233110","phase":"PHASE1","title":"Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD","status":"RECRUITING","sponsor":"Stefanie Sarantopoulos, MD, PhD.","startDate":"2025-10-29","conditions":"Chronic Graft Versus Host Disease","enrollment":30},{"nctId":"NCT07357441","phase":"","title":"A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-04-07","conditions":"Myelofibrosis","enrollment":355},{"nctId":"NCT07356245","phase":"PHASE2","title":"Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma","status":"RECRUITING","sponsor":"Jonathan Brammer","startDate":"2026-02-01","conditions":"T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell","enrollment":44},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT03222609","phase":"PHASE2","title":"A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-31","conditions":"Myelofibrosis (MF)","enrollment":191},{"nctId":"NCT06887803","phase":"PHASE1, PHASE2","title":"A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors","status":"RECRUITING","sponsor":"iOnctura","startDate":"2025-11-17","conditions":"Myelofibrosis (MF)","enrollment":26},{"nctId":"NCT06768476","phase":"PHASE1","title":"CART123 + Ruxolitinib in Relapsed/Refractory AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-02-28","conditions":"Relapsed AML, Refractory AML","enrollment":12},{"nctId":"NCT07340723","phase":"PHASE2","title":"Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-06-01","conditions":"GVHD,Acute, Stem Cell Transplant Complications","enrollment":168},{"nctId":"NCT07219576","phase":"PHASE1, PHASE2","title":"Retifanlimab and Ruxolitinib In Solid Malignancies","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-01-08","conditions":"Non Small Cell Lung Carcinoma, Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT04370301","phase":"PHASE2","title":"Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-02-09","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":20},{"nctId":"NCT06008808","phase":"PHASE1","title":"Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-07","conditions":"Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease","enrollment":41},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT04468984","phase":"PHASE3","title":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-31","conditions":"Myelofibrosis (MF)","enrollment":330},{"nctId":"NCT04644211","phase":"PHASE2","title":"Ruxolitinib in Thrombocythemia and Polycythemia Vera","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-21","conditions":"Essential Thrombocythemia, Polycythemia Vera","enrollment":60},{"nctId":"NCT05371964","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis","status":"RECRUITING","sponsor":"Geron Corporation","startDate":"2022-05-04","conditions":"Myelofibrosis","enrollment":36},{"nctId":"NCT07128381","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-01-02","conditions":"Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)","enrollment":66},{"nctId":"NCT07153666","phase":"","title":"A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-12-08","conditions":"Vitiligo","enrollment":170},{"nctId":"NCT07311746","phase":"PHASE1, PHASE2","title":"Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-01","conditions":"T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia","enrollment":36},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT06991101","phase":"PHASE2","title":"Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2025-12-03","conditions":"Glioblastoma, Brain Cancer, Glioblastoma Multiforme","enrollment":190},{"nctId":"NCT07249346","phase":"PHASE2","title":"Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hannah Choe, MD","startDate":"2026-06-01","conditions":"Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia","enrollment":124},{"nctId":"NCT04455841","phase":"PHASE1, PHASE2","title":"INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-03-19","conditions":"Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":84},{"nctId":"NCT03801434","phase":"PHASE2","title":"Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders","status":"RECRUITING","sponsor":"William Shomali","startDate":"2019-11-15","conditions":"BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells","enrollment":10},{"nctId":"NCT07297914","phase":"PHASE2, PHASE3","title":"Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","status":"NOT_YET_RECRUITING","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2026-01-15","conditions":"Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease","enrollment":1000},{"nctId":"NCT06160791","phase":"PHASE2","title":"Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)","status":"RECRUITING","sponsor":"Jerry Lee, MD, MSc, MPhil","startDate":"2024-10-01","conditions":"Hemophagocytic Lymphohistiocytoses","enrollment":36},{"nctId":"NCT05696392","phase":"PHASE4","title":"The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2023-03-16","conditions":"Atopic Dermatitis","enrollment":47},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia","enrollment":60},{"nctId":"NCT06832618","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-17","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT03654768","phase":"PHASE2","title":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-10-24","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":81},{"nctId":"NCT05764161","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2023-06-12","conditions":"Prurigo Nodularis","enrollment":190},{"nctId":"NCT06548360","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-01-24","conditions":"NonSegmental Vitiligo","enrollment":180},{"nctId":"NCT06804811","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-11-13","conditions":"NonSegmental Vitiligo","enrollment":250},{"nctId":"NCT04603495","phase":"PHASE3","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-09","conditions":"Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":430},{"nctId":"NCT02955940","phase":"PHASE2","title":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2016-11-30","conditions":"Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer","enrollment":10},{"nctId":"NCT07283822","phase":"PHASE2","title":"Amping up With PemJAK","status":"RECRUITING","sponsor":"Seda S. Tolu","startDate":"2025-12-03","conditions":"Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed","enrollment":53},{"nctId":"NCT06615050","phase":"PHASE3","title":"A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-04-02","conditions":"Graft-versus-host Disease (GVHD)","enrollment":572}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":3742,"therapeuticAreas":["Bone"],"_revenueScrapedAt":"2026-04-08 13:57:22.85424+00","biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Jakafi","genericName":"RUXOLITINIB","companyName":"Incyte Corp","companyId":"","modality":"Small molecule","firstApprovalDate":"2011","aiSummary":"Jakafi (Ruxolitinib) is a Janus Kinase Inhibitor developed by Incyte Corp, targeting the Tyrosine-protein kinase JAK2. It is a small molecule modality approved by the FDA in 2011 for various myeloproliferative disorders, graft-versus-host disease, and other conditions. Jakafi is a patented medication with no generic manufacturers available. Key safety considerations include the risk of anemia, thrombocytopenia, and neutropenia. Jakafi's commercial status remains unchanged as it is still under patent.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":"EMEA/H/C/005843"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Opzelura","application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":113,"withResults":19},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}